Abstract
Background: The number of nanoproducts on the market will increase in the next years. The development of analytical methods comprising conventional and novel pharmaceutical dosage forms and drug delivery, under same conditions in order to save money, time and to reduce the environmental impact of residues, is demanding.
Objective: The aim of this study was to develop a high performance liquid chromatography (HPLC) method to assay doxazosin in polymeric nanocapsules and tablets under the same chromatographic conditions. Method: As stationary phase, a reversed-phase column C-18 was used. The mobile phase was composed of a mixture of acetonitrile, acidified water (80:20 v/v). Detection was performed at 248 nm. Validation analysis were carried out according to the official requirements. Results: A linear relationship was observed between the concentration of doxazosin and the chromatographic area in the range between 5 and 40 μg.mL-1. The limits of quantification and detection were 0.756 and 0.252 μg.mL-1, respectively. The method was precise (intra- and inter-day), showing values of relative standard deviation below 2%. Accuracy was demonstrated in the mean doxazosin recovery values of 98% for nanocapsules and 95% for tablets. Conclusion: This simple and inexpensive method may be used to determine doxazosin in nanocapsule suspension as well tablets, under identical chromatographic conditions.Keywords: Doxazosin, liquid chromatography, tablets, nanocapsules, nanoparticles, validation.
Graphical Abstract